AzurBio Consulting

We are launching AzurBio Consulting! AzurBio Consulting is a new brand dedicated to providing tailored strategic and operational consulting services for pharmaceutical, biotechnology, and medical device companies. This new company is born from AzurBio Pharma's acquisition of A-pharmaconsult, a leading European regulatory consultancy with over 30 years of experience. 💡 Why is this important? By combining A-pharmaconsult’s renowned regulatory expertise with AzurBio Pharma’s innovative and agile approach, we are strengthening our ability to support companies throughout the entire healthcare product lifecycle—from development to commercialization. 🔹What AzurBio Consulting Offers: ✅ European development & regulatory strategy ✅ Scientific writing & regulatory submissions ✅ Quality management solutions ✅ End-to-end support in navigating complex regulatory landscapes Learn more: www.azurbio-consulting.com

PN Update: European Shortages Monitoring Platform fully operational for monitoring of shortages in the EU

PN Update: Human medicines European public assessment report (EPAR): Galvus, vildagliptin, Date of authorisation: 25/09/2007, Revision: 24, Status: Authorised

PN Update: Human medicines European public assessment report (EPAR): Prometax, rivastigmine, Date of authorisation: 04/12/1998, Revision: 48, Status: Authorised

PN Update: European Shortages Monitoring Platform (ESMP): Marketing authorisation holder reporting templates

PN Update: European Shortages Monitoring Platform (ESMP) release notes

PN Update: European Shortages Monitoring Platform (ESMP): Implementation guide for national competent authorities

PN Update: European Shortages Monitoring Platform (ESMP) User guide for marketing authorisation holders

PN Update: European Shortages Monitoring Platform (ESMP): National competent authority reporting templates

PN Update: European Shortages Monitoring Platform (ESMP): Implementation guide for marketing authorisation holders